Molnupiravir and Vaccine Boosters for COVID-19 – Two New MedCram Updates

Post Overview
    Add a header to begin generating the table of contents

     

    Two recent MedCram video updates cover the latest information on a potential COVID-19 treatment, Molnupiravir, as well as unfolding news on vaccine booster shots. 

     

    Merck COVID Pill (Molnupiravir): A New Treatment Option?

    In MedCram COVID-19 update 130, Dr. Seheult discusses Merck’s announcement of their antiviral pill for the treatment of mild to moderate SARS-CoV-2 infection. The drug, Molnupiravir, was submitted for FDA emergency-use authorization after undergoing initial trials by Merck for effectiveness in at-risk, non-hospitalized patients who tested positive for COVID-19.

    Dr. Seheult explains the mechanisms of Molnupiravir — how it impairs SARS-CoV-2 viral replication — and the specific types of COVID-19 patients for which the medication is currently intended. Dr. Seheult also compares this treatment to monoclonal antibodies, highlighting the importance  of accessibility and ease of a pill versus an IV treatment (monoclonal antibodies).

     

    Mixing Vaccine Boosters For COVID-19

    In our 131st COVID-19 video update, Dr. Seheult talks about FDA recommendations to the CDC on booster vaccines and mixing and matching. The FDA news release from October 20, 2021 details the FDA’s proposals, which will then need to go to the CDC and be signed off by the CDC director before taking effect. In our video, Dr. Seheult clearly explains and outlines these booster shot recommendations for each of the vaccines available in the United States: Pfizer-BioNTech, Moderna, and Johnson & Johnson.

     

    Stay Tuned for More COVID-19 Updates 

    Our COVID-19 videos are always available for free (and ad-free) at MedCram.com. In addition, check out our full library of courses and lectures on subjects ranging from Cardiology to The Adrenal Gland Explained Clearly and many more!

    Leave a Comment